Fresh Versus Freeze-only After CAPA IVM on PCOS Patients

PCOS Clinical Trial

Official title:

Outcomes of Fresh Transfer Versus Freeze-only After CAPA IVM on PCOS Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04297553
• Other study ID #: CS/BVMÐPN/20/01
• Status: Completed
• Phase: N/A
• Start date: March 6, 2020
• Est. completion date: December 15, 2020

Study information

• Verified date: February 2021
• Source: M? Ð?c Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

IVM (in vitro maturation) has been proved to be a more friendly treatment protocol for PCOS (polycystic ovary syndrome) patients compared with conventional controlled ovarian stimulation, with less complications (especially ovarian hyperstimulation syndrome), shorter treatment duration, lower cost, and acceptable pregnancy outcomes.

Description:

IVM (in vitro maturation) has been proved to be a more friendly treatment protocol for PCOS (polycystic ovary syndrome) patients compared with conventional controlled ovarian stimulation, with less complications (especially ovarian hyperstimulation syndrome), shorter treatment duration, lower cost, and acceptable pregnancy outcomes. CAPA (capacitation) IVM without hCG (human chorionic gonadotropin) priming, has routinely been used at My Duc hospital for nearly 3 years to replace hCG-IVM (with hCG priming) because of absolutely synchronized oocyte maturation stage and better embryo results and better pregnancy outcomes. However, with CAPA IVM, embryos are freezed-only and will be transferred in the next cycles. This process will increase the cost of freezing and thawing embryos, and increase the treatment duration, which complicates the IVM procedure and turns IVM into an unfriendly protocol to PCOS patients. Therefore, our group conducts this study to find out the effectiveness of fresh transfer protocol after CAPA IVM compared with freezing-only CAPA IVM protocol. The fresh transfer protocol for CAPA IVM is applied from previous hCG IVM protocol, with the use of hCG and exogenous estradiol and progesterone, but at different timings.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: December 15, 2020
• Est. primary completion date: August 18, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 37 Years

Eligibility

Inclusion Criteria:

• Women with high AFC (=24 Antral Follicles in Both Ovaries), including PCOS plus PCO or high AFC
• Having indications for ART
• Having = 2 IVM/IVF attempts
• Permanent resident in Vietnam
• Agree to have fresh embryos transfer or freeze-only on day 3
• Agree to have = 2 embryos transferred
• Not participating in another IVF study at the same time

Exclusion Criteria:

• Oocyte donation cycles
• Pre-implantation genetic diagnosis (PGD) cycles

Related Conditions & MeSH terms

• Embryo Transfer
• IVM
• PCOS

Intervention

Procedure:
• CAPA-Fresh
Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Receiving hCG 5000IU x 2 (10000IU) after Oocytes retrieval. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Fresh embryos transfer will be performed on day 3 using HRT protocol with a maximum of 2 embryos transferred.
• CAPA-Freeze-only
Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.

Locations

Country	Name	City	State
Vietnam	M? Ð?c Hospital	Ho Chi Minh City	Tan Binh

Sponsors (1)

Lead Sponsor	Collaborator
M? Ð?c Hospital

Country where clinical trial is conducted

Vietnam, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ongoing pregnancy resulting in live birth after the first embryo transfer of the started treatment cycle.	Live birth is defined as the birth of at least one newborn after 24 weeks' gestation that exhibits any sign of life (twin will be a single count).; For the timing of this occur, ongoing pregnancy will be used, conditional on the fact that this ongoing pregnancy results in live birth.	At 24 weeks of gestation
Secondary	Positive pregnancy test	Serum human chorionic gonadotropin level greater than 5 mIU/mL	at 2 weeks after the embryo placement after the completion of the first transfer
Secondary	Clinical pregnancy	at least one gestational sac on ultrasound at 7 weeks' gestation with the detection of heart beat activity	5 weeks after embryo placement after the completion of the first transfer
Secondary	Implantation rate	as the number of gestational sacs per number of embryos transferred	3 weeks after embryo transferred after the completion of the first transfer
Secondary	Ongoing pregnancy	Ongoing pregnancy is defined as pregnancy with detectable heart rate at 12 weeks' gestation or beyond, after the completion of the first transfer	At 12 weeks' gestation
Secondary	Number of embryos on day 3	Number of embryos on day 3	5 days after oocytes pick-up
Secondary	Number of good quality embryo on day 3	good quality embryos are defined followed Istanbul consensus	5 days after oocytes pick-up
Secondary	Time from randomisation to ongoing pregnancy	Time from randomization to ongoing pregnancy after the completion	12 weeks of gestation after the completion of the first transfer
Secondary	Time from randomisation to live birth	Time from randomization to live birth after the completion	At the time of delivery
Secondary	Ovarian hyperstimulation syndrome (OHSS)	Routine assessments for OHSS were performed on day 3 post oocyte retrieval in both groups. At other times, OHSS was evaluated if symptoms were reported by the patient. OHSS was classified using the flow diagram developed by Humaidan and colleagues for use in clinical trial settings	at 03 days after oocytes pick-up and 14 days after embryo transfer
Secondary	Ectopic pregnancy	a pregnancy in which implantation takes place outside the uterine cavity after the completion of the first transfer	at 12 weeks of gestation after the completion of the first transfer
Secondary	Miscarriage	pregnancy loss at < 24 weeks	at 24 weeks of gestation after the completion of the first transfer
Secondary	Hypertensive disorders of pregnancy	Pregnancy-induced hypertension, pre-eclampsia and eclampsia	at 20 weeks of gestation or beyond after the completion of the first transfer
Secondary	Gestational diabetes mellitus	using a 75g oral glucose tolerance test	at 24 weeks of gestation after the completion of the first transfer
Secondary	Preterm delivery	Multiple definitions, defined as delivery at <24, <28, <32, <37 completed weeks	at 24, 28, 32 weeks and 37 weeks of gestation after the completion of the first transfer
Secondary	Multiple pregnancy	Defined as presence of more than one sac at early pregnancy ultrasound (6-8 weeks gestation)	5 weeks after embryo placement after the completion of the first transfer
Secondary	Birth weight	Weight of singletons and twins	at the time of delivery
Secondary	Congenital anomaly	Any congenital anomaly will be included	At birth after the completion of the first transfer
Secondary	Cost-effectiveness	Including direct and indirect costs; costs related to complications treatment. Cost data will be collected for a supplementary analysis and will be reported in a separated paper.	Two year after randomization